FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...
A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...
A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings. Patients with inflammatory bowel disease (IBD) who transitioned from ...
CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis treatment, enhancing access and affordability. CT-P47, a biosimilar candidate ...
While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...
Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness. A real-world, economic evaluation based on a ...
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost ...
The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback